Additionally, the 36-month beta value for ADAP is 2.26. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for ADAP is 226.52M and currently, short sellers hold a 1.96% ratio of that float. The average trading volume of ADAP on May 13, 2025 was 1.70M shares.
ADAP) stock’s latest price update
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP)’s stock price has dropped by -5.83 in relation to previous closing price of 0.30. Nevertheless, the company has seen a loss of -7.33% in its stock price over the last five trading days. newsfilecorp.com reported 2025-05-13 that TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity 1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – May 13, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March 31, 2025.
ADAP’s Market Performance
Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a -7.33% fall in stock performance for the past week, with a 25.06% rise in the past month, and a -51.74% drop in the past quarter. The volatility ratio for the week is 6.71%, and the volatility levels for the past 30 days are at 8.94% for ADAP. The simple moving average for the past 20 days is 1.63% for ADAP’s stock, with a -59.36% simple moving average for the past 200 days.
Analysts’ Opinion of ADAP
Many brokerage firms have already submitted their reports for ADAP stocks, with H.C. Wainwright repeating the rating for ADAP by listing it as a “Buy.” The predicted price for ADAP in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on July 30, 2024 of the previous year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see ADAP reach a price target of $3.15. The rating they have provided for ADAP stocks is “Sector Outperform” according to the report published on May 30th, 2024.
Bryan Garnier gave a rating of “Buy” to ADAP, setting the target price at $3.60 in the report published on March 24th of the previous year.
ADAP Trading at -10.46% from the 50-Day Moving Average
After a stumble in the market that brought ADAP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.22% of loss for the given period.
Volatility was left at 8.94%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares surge +15.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.88% lower at present.
During the last 5 trading sessions, ADAP fell by -9.57%, which changed the moving average for the period of 200-days by -79.13% in comparison to the 20-day moving average, which settled at $0.2732. In addition, Adaptimmune Therapeutics Plc ADR saw -48.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADAP starting from Norry Elliot, who sale 5,584 shares at the price of $0.58 back on Jan 17 ’25. After this action, Norry Elliot now owns 7,510 shares of Adaptimmune Therapeutics Plc ADR, valued at $3,243 using the latest closing price.
Lunger John, the Chief Patient Supply Officer of Adaptimmune Therapeutics Plc ADR, sale 5,584 shares at $0.58 during a trade that took place back on Jan 17 ’25, which means that Lunger John is holding 7,510 shares at $3,243 based on the most recent closing price.
Stock Fundamentals for ADAP
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.95 for the gross margin
The net margin for Adaptimmune Therapeutics Plc ADR stands at -0.4. The total capital return value is set at -0.38. Equity return is now at value -273.36, with -26.56 for asset returns.
Based on Adaptimmune Therapeutics Plc ADR (ADAP), the company’s capital structure generated 0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -0.99. The debt to equity ratio resting at 6.26. The interest coverage ratio of the stock is -20.54.
Currently, EBITDA for the company is -52.66 million with net debt to EBITDA at 0.3. When we switch over and look at the enterprise to sales, we see a ratio of 0.31. The receivables turnover for the company is 11.14for trailing twelve months and the total asset turnover is 0.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.92.
Conclusion
In conclusion, Adaptimmune Therapeutics Plc ADR (ADAP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
